Hermetica Superfood Encyclopedia
The Short Answer
Copaibo oleoresin delivers sesquiterpenes including β-caryophyllene and trans-α-bergamotene alongside diterpenoids such as kaurenoic acid and copalic acid, which collectively suppress pro-inflammatory mediators and scavenge free radicals through antioxidant mechanisms. In preclinical rat models, oral oleoresin at 400 mg/kg provided complete protection against indomethacin-induced gastric ulcers, and leaf flavonoids exhibited DPPH free radical inhibition with EC50 values comparable to quercetin at 1.94 µg/mL.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary Keywordcopaibo benefits
Copaibo — botanical close-up
Health Benefits
**Anti-Inflammatory Activity**
Diterpenoids kaurenoic acid and copalic acid inhibit pro-inflammatory mediators, reducing tissue inflammation; β-caryophyllene further contributes via cannabinoid receptor CB2 agonism and downstream cytokine suppression.
**Gastroprotection**
Oral oleoresin at 200–400 mg/kg dose-dependently protected rat gastric mucosa against ethanol- and indomethacin-induced lesions, with 400 mg/kg achieving complete ulcer prevention in controlled preclinical trials.
**Antioxidant Defense**
Flavonoids including quercitrin and galloylquinic acids in leaf extracts scavenge reactive oxygen species with potency comparable to reference standards; supercritical CO2 extraction yields flavonoid concentrations 10-fold higher than conventional methanol extraction.
**Antimicrobial Properties**
Sesquiterpenes and diterpenoids in the oleoresin demonstrate broad-spectrum antimicrobial activity against bacterial and fungal pathogens in vitro, supporting its traditional use in wound care and infection management.
**Wound Healing Support**
Traditional and pharmacological evidence supports oleoresin application for wound healing via combined anti-inflammatory, antimicrobial, and tissue-protective mechanisms attributable to its complex sesquiterpene-diterpenoid matrix.
**Antitumor Potential**: Clerodane diterpenoids isolated from C
langsdorffii show in vitro cytotoxic activity against tumor cell lines, as reported in early Japanese phytochemical studies from 1994, though no human oncology data exist.
**Antiparasitic Effects**
Folk medicine applications and preliminary in vitro data indicate activity against protozoan parasites, consistent with the high sesquiterpene content that disrupts microbial membrane integrity.
Origin & History
Natural habitat
Copaifera langsdorffii is a large leguminous tree native to the Brazilian cerrado and Amazon basin, distributed widely across South America in humid tropical and subtropical forests. It thrives in well-drained, nutrient-poor savanna soils and reaches heights of 10–40 meters, producing oleoresin in trunk cavities that can be tapped without felling the tree. Cultivation is largely wild-harvest based, with oleoresin extraction practiced by indigenous and traditional communities across Brazil, Bolivia, and Colombia for centuries.
“Copaifera oleoresin has been documented in Brazilian indigenous medicine for at least several centuries, with early European naturalists recording its use by Amazonian tribes for wound healing, respiratory conditions, urinary tract infections, and as an anti-inflammatory agent during the colonial period. The resin's medicinal reputation spread through Portuguese Brazil, becoming a staple of Brazilian folk pharmacopoeia under the name 'óleo de copaíba,' and it remains commercially traded in Amazonian markets today. Preparation traditionally involves drilling or naturally tapping the trunk to collect the golden-amber oleoresin, which may be consumed neat, blended with other plant medicines, or applied topically, with tree tapping performed sustainably to preserve the source tree. Scientific interest intensified in the 1990s when Japanese researchers isolated antitumor clerodane diterpenoids from the species, bridging ethnobotanical knowledge with modern phytochemical investigation.”Traditional Medicine
Scientific Research
The current evidence base for Copaifera langsdorffii is entirely preclinical, comprising in vitro assays and rodent models with no published human clinical trials reporting sample sizes, effect sizes, or controlled outcomes as of the available literature. Rat gastroprotection studies used n=12 animals per group with oral oleoresin doses of 200–400 mg/kg, demonstrating dose-dependent protection; antioxidant studies used standardized DPPH and TEAC colorimetric assays reporting EC50 values in the low µg/mL range. Phytochemical characterization studies, including GC-MS profiling of oleoresin and supercritical fluid extract optimization, provide robust compositional data but do not translate directly to clinical efficacy. The overall quality of evidence is low by clinical standards: no randomized controlled trials, no pharmacokinetic studies in humans, and no established bioavailability data exist, placing this ingredient firmly in the preliminary-evidence category.
Preparation & Dosage
Traditional preparation
**Raw Oleoresin (oral)**
200–400 mg/kg in rats; no validated human equivalent dose established; traditionally consumed directly as a tonic oil in small volumes (1–5 mL)
Used in preclinical models at .
**Supercritical CO2 Extract**
Preferred method for flavonoid enrichment, yielding up to 10-fold higher flavonoid concentration than methanol extracts; kaurenoic acid content up to 44.3% achievable; no human dosing guidelines defined.
**Leaf Extract (methanol or supercritical)**
Used in antioxidant and phytochemical studies; standardized to quercitrin, galloylquinic acid, or β-caryophyllene content for research purposes; no commercial supplement standardization established.
**Traditional Oral Oil**
Trunk-tapped oleoresin consumed directly or diluted in water or plant-based preparations by indigenous practitioners for inflammation, gastric complaints, and wound care.
**Topical Application**
Raw oleoresin or diluted extract applied directly to wounds and inflamed tissue in traditional practice; no standardized topical formulation or concentration guideline exists in clinical literature.
**Timing**
Traditional use is not tied to specific timing protocols; preclinical oral dosing was acute or subacute; chronic supplementation protocols in humans are undefined.
Nutritional Profile
Copaibo is not a significant source of conventional macronutrients or micronutrients, as it is used as a resin extract rather than a food. The oleoresin is composed primarily of volatile sesquiterpenes (β-caryophyllene up to 32.8%, trans-α-bergamotene up to 48.4%, germacrene D variable) and non-volatile diterpenoids (kaurenoic acid up to 44.3%, copalic acid ~5.6%, hardwickiic acid ~8.2%), with negligible protein, carbohydrate, or mineral content. Leaf fractions contain flavonoids including quercitrin and galloylquinic acid derivatives, with supercritical CO2 leaf extracts yielding approximately 10-fold higher flavonoid concentrations than methanol reference extracts, suggesting strong polarity-selective bioavailability during extraction. Bioavailability of diterpenoids and sesquiterpenes from oral oleoresin in humans is unstudied; the high lipophilicity of kaurenoic acid (soluble in hexane and ethyl acetate) suggests absorption via lymphatic pathways, but no human pharmacokinetic data confirm this.
How It Works
Mechanism of Action
β-Caryophyllene, the dominant sesquiterpene in copaibo oleoresin and leaves (1.1–32.8% and 5.7–17.5% respectively), functions as a selective agonist of cannabinoid receptor type 2 (CB2), activating anti-inflammatory signaling cascades that reduce NF-κB-mediated transcription of pro-inflammatory cytokines such as TNF-α and IL-6 without psychoactive CB1 activity. Diterpenoids kaurenoic acid and copalic acid are hypothesized to inhibit cyclooxygenase (COX) enzymes and reduce prostaglandin biosynthesis, though specific receptor-level mechanistic confirmation in peer-reviewed sources is not yet fully detailed. Flavonoids including quercitrin and galloylquinic acids contribute to antioxidant activity by directly scavenging hydroxyl and peroxyl radicals and chelating transition metals, as quantified by DPPH and TEAC assays. Gastroprotective effects appear to involve cytoprotective mechanisms in gastric mucosa, likely mediated by the combined resin matrix reducing oxidative damage and modulating mucosal prostaglandin tone rather than a single isolated pathway.
Clinical Evidence
No human clinical trials have been conducted or published for Copaifera langsdorffii in any indication as of the available research record, making direct clinical translation impossible. Available preclinical data from rat models indicate meaningful gastroprotective effects at 400 mg/kg oral oleoresin, achieving complete ulcer prevention against indomethacin challenge, but rodent-to-human dose extrapolation is unreliable without bridging pharmacokinetic studies. In vitro antitumor and antimicrobial data provide mechanistic hypotheses but do not constitute clinical evidence of efficacy or safety in humans. Confidence in any health application beyond traditional use remains low, and all benefit claims should be considered hypothesis-generating rather than clinically validated.
Safety & Interactions
Human safety data for Copaifera langsdorffii are essentially absent from the clinical literature; no adverse effects were reported in rat studies at 200–400 mg/kg oral oleoresin, but long-term toxicology, genotoxicity, and carcinogenicity studies in any species are not documented in available sources. No specific drug interactions have been characterized, though the high diterpenoid and flavonoid content theoretically presents risks of interaction with cytochrome P450 metabolized drugs (particularly CYP3A4 substrates) and anticoagulants, given the anti-inflammatory and antioxidant mechanisms involved. Contraindications are undefined in the evidence base; however, high-dose oleoresin should be used with caution in individuals with liver or kidney disease given the metabolic burden of concentrated diterpenoids. Pregnancy and lactation safety is entirely unestablished, and use during these periods is not recommended given the complete absence of human safety data and the biological activity of kaurenoic acid and β-caryophyllene.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Copaifera langsdorffiiCopaíbaÓleo de copaíbaCopaiba balsamDiesel tree resin
Frequently Asked Questions
What is copaibo used for?
Copaibo oleoresin from Copaifera langsdorffii is used in Brazilian traditional medicine for anti-inflammatory, wound healing, gastroprotective, antimicrobial, and antiparasitic purposes. Its primary bioactive compounds are sesquiterpenes like β-caryophyllene and diterpenoids like kaurenoic acid, which suppress inflammatory mediators and scavenge free radicals. All current evidence is preclinical; no human clinical trials have validated these uses.
What does copaibo do for inflammation?
Copaibo contains β-caryophyllene, a sesquiterpene that acts as a CB2 cannabinoid receptor agonist and suppresses NF-κB-driven pro-inflammatory cytokine production, and diterpenoids kaurenoic acid and copalic acid that are hypothesized to inhibit COX enzymes. These mechanisms have been observed in vitro and in rodent models but have not been confirmed in human clinical trials. Its anti-inflammatory activity is considered promising but preliminary.
Is copaibo safe to take?
Human safety data for copaibo are not established in the clinical literature. Rat studies using oral oleoresin at doses up to 400 mg/kg reported no adverse effects, but long-term toxicology, drug interaction profiles, and genotoxicity studies are absent. Use during pregnancy and lactation is not recommended due to the complete lack of human safety evidence, and individuals on medications metabolized by CYP3A4 enzymes should exercise caution.
What is the recommended dosage of copaibo?
No standardized human dosage for copaibo has been established in clinical research. Preclinical gastroprotection studies in rats used 200–400 mg/kg oral oleoresin, which does not directly translate to human dosing without pharmacokinetic bridging data. Traditional Brazilian folk use typically involves small volumes of raw oleoresin (approximately 1–5 mL), but this practice lacks clinical validation or safety monitoring.
What are the main compounds in copaibo oleoresin?
Copaibo oleoresin is primarily composed of sesquiterpenes including β-caryophyllene (1.1–32.8%) and trans-α-bergamotene (up to 48.4%), alongside non-volatile diterpenoids such as kaurenoic acid (up to 44.3%), copalic acid (~5.6%), and hardwickiic acid (~8.2%). Leaf extracts additionally contain flavonoids like quercitrin and galloylquinic acids, which contribute antioxidant activity with EC50 values comparable to quercetin. Composition varies significantly by geographic origin and extraction method, with supercritical CO2 extraction yielding 10-fold higher flavonoid concentrations than methanol extraction.
Does copaibo interact with common medications like NSAIDs or blood thinners?
Copaibo contains compounds that may potentiate anticoagulant effects and could theoretically interact with blood thinners like warfarin or NSAIDs due to its anti-inflammatory activity. Since copaibo itself has mild anticoagulant properties via its diterpenoid content, concurrent use with anticoagulants or antiplatelet drugs warrants medical supervision. Consult your healthcare provider before combining copaibo with prescription medications, especially those affecting inflammation or clotting.
Is copaibo safe during pregnancy or for nursing mothers?
There is insufficient clinical data on copaibo safety during pregnancy and lactation, so it is generally not recommended without explicit medical approval during these periods. Animal studies have evaluated gastric protection at high doses, but human reproductive safety data remains limited. Pregnant and nursing women should consult their healthcare provider before using copaibo supplements.
What is the most bioavailable form of copaibo—liquid oleoresin, capsules, or standardized extracts?
Copaibo oleoresin in liquid form typically offers superior bioavailability compared to capsules due to direct absorption of the volatile and semi-volatile compounds, though capsules provide better stability and convenience. Standardized extracts with defined levels of kaurenoic acid and copalic acid may enhance consistency and therapeutic efficacy, though absorption rates depend on formulation quality and individual digestive factors. Sublingual or oil-based delivery forms may improve absorption of lipophilic diterpenoids compared to dry extracts.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w copaibo-copaifera-langsdorffii curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
